Current concepts about inhibition of platelet aggregation

Platelets

Volumn 19, Issue 8, 2008, Pages 565-570

  De Gaetano, Giovanni ^a   Crescente, Marilena ^a   Cerletti, Chiara ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antiplatelet; Antiplatelet drugs; Aspirin resistance; Platelet function tests; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; PRASUGREL; TICAGRELOR; TICLOPIDINE;

BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL RESEARCH; CONSENSUS; DRUG EFFICACY; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW; SCREENING; STANDARDIZATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT CONTRAINDICATION; VALIDITY;

CARDIOVASCULAR DISEASES; DRUG MONITORING; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TREATMENT OUTCOME;

EID: 56549126982     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100802485947     Document Type: Review

References (52)

1. Bizzozero J. Uber einen neuen forrnbestandteil des blutes und dessen rolle bei der thrombose und blutgerinnung. Arch Pathol Anat Phys Klin Med 1882;90:261-332.
2. de Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 2001;86:349-356.
3. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1974;1:436-440.
4. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100:261-275.
5. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
6. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
8. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
9. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA. et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
10. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM. et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372.
11. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. American Heart Association; American College of Cardiology; Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the Americam Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-818.
12. de Gaetano G, Cerletti C. Platelet function, antiplatelet therapy and clinical outcomes: To test or not to test? J Thromb Haemost 2007;5:1835-1838.
13. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003;1:1628-1636.
14. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929.
15. Philipp CS, Dilley A, Miller CH, Evatt B, Baranwal A, Schwartz R, Bachmann G, Saidi P. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003;1:477-484.
16. Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am J Cardiol 2006;98:4N-10N.
17. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007;167:1593-1599.
18. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by platelet function analyzer (PFA-100): A systematic review. Thromb Haemost 2008;99:14-26.
19. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. Br Med J 2008;336:195-198.
20. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2008;6:444-450.
21. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C. PFA-100 ® closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3003 patients. Thromb Haemost 2008;99:1129-1131.
22. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - A meta-analysis. Int J Cardiol 2008;128:166-171.
23. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
24. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
25. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826.
26. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549.
27. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
28. Hayward CP, Eikelboom J. Platelet function testing: Quality assurance. Semin Thromb Hemost 2007;33:273-282.
29. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-231.
30. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007;18:199-206.
31. Goa KL, Noble S. Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999;57:439-462.
32. Shpilberg O, Rabi I, Schiller K, Walden R, Harats D, Tyrrell KS, Coller B, Seligsohn U. Patients with Glanzmann thrombasthenia lacking platelet glycoprotein alpha(IIb)beta(3) (GPIIb/IIIa) and alpha(v)beta(3) receptors are not protected from atherosclerosis. Circulation 2002;105:1044-1048.
33. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.
34. Leslie J, Mason DY. Sensitivity of platelets to aspirin in von Willebrand's disease. J Clin Pathol 1970;23:526-528.
35. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003;34:849-854.
36. Nadell J, Bruno J, Varady J, Segre EJ. Effect of naproxen and of aspirin on bleeding time and platelet aggregation. J Clin Pharmacol 1974;14:176-182.
37. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968;47:2169-2180.
38. Clagett GP, Collins GJ. Platelets, thromboembolism and the clinical utility of antiplatelet drugs. Surg Gynecol Obstet 1978;147:257-272.
39. de Gaetano G, Cerletti C, Bertelé V. Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: A difficult link. Lancet 1982;2:974-977.
40. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP. North American Specialized Coagulation Laboratory Association. Variability in clinical laboratory practice in testing for disorders of platelet function: Results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005;93:549-553.
41. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
42. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-1987.
43. Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007;121:107-115.
44. Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006;96:767-773.
45. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5:1839-1847.
46. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: A meta-analysis. Thromb Haemost 2001;85:626-633.
47. Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med 2003;22:1741-1760.
48. Cavallari U, Trabetti E, Malerba G, Biscuola M, Girelli D, Olivieri O, Martinelli N, Angiolillo DJ, Corrocher R, Pignatti PF. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet 2007;8:59.
49. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, Sabeti S, Amighi J, Minar E, Brunner M. et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005;36:1394-1399.
50. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367:651-658.
51. Rozalski M, Boncler M, Luzak B, Watala C. Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacol Rep 2005;57:1-13.
52. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: A comprehensive systematic review. Br J Clin Pharmacol 2008;66:222-232.